GreenVax Selects Xcellerex XDR Single-Use Bioreactors for New Vaccine and Biotherapeutics Program

MARLBOROUGH, Mass.--(BUSINESS WIRE)--Xcellerex, Inc. announced today that Project GreenVax has agreed to acquire XDR GMP single-use production bioreactors from Xcellerex. The systems will be deployed in a new facility currently under construction in Bryan, Texas. Project GreenVax is spearheaded by Texas Plant-Expressed Vaccine Consortium, which consists of G-Con, LLC and The Texas A&M University System. Financial terms were not disclosed.

“The XDR system was selected for several reasons, including competitive capital costs, and a lower overall operating cost compared to that of conventional steam-in-place reactors.”

“The XDR system has been demonstrated to be very adaptable and effective in growing wide variety of organisms to support our process needs,” commented Dr. Barry Holtz, president of G-Con. “The XDR system was selected for several reasons, including competitive capital costs, and a lower overall operating cost compared to that of conventional steam-in-place reactors."

Xcellerex founder and Chief Technology Officer Parrish Galliher added, “The GreenVax project is an exciting outgrowth of the work we have been doing over the past several years with DARPA’s Accelerated Manufacture of Pharmaceuticals program. GreenVax has developed a very innovative process and we are pleased they selected the XDR system as an important part of their production train.”

Project GreenVax, which utilizes tobacco plants rather than the current egg-based vaccine technology, holds the promise of shortening vaccine production to a fraction of the current time, allowing rapid response to newly emerging viruses not possible with current technology.

Project GreenVax was designed for a projected final scale capacity of 100 million doses per month. The flexibility of the plant-based system, combined with its low cost and ability to massively scale, may provide vaccine protection not only to citizens of the United States, but to many parts of the world that cannot currently afford vaccines.

The GreenVax Project will be headquartered on a secure, 21-acre site on the campus of the Texas A&M Health Science Center in Bryan, Texas. The custom-designed 145,000 square foot biotherapeutic production facility will be constructed and managed by G-Con.

About Xcellerex, Inc.

Xcellerex is revolutionizing the way biomolecules are developed, manufactured and commercialized. The company’s unique single-use component technology platform transforms biomanufacturing economics, enabling the development of biotherapeutics and vaccines, and dramatically improving the ability of Xcellerex and its partners to deploy manufacturing capacity.

Xcellerex leverages its technology and services platform by: 1) commercializing its FlexFactories® (complete, turnkey, modular production facilities) and enabling single-use unit operations (unique, integrated XDR bioreactors, XDM mixing systems and related single-use assemblies)and 2) enabling its partners to accelerate time-to-GMP manufacturing and the clinic by leveraging it FlexFactory manufacturing know-how, services capacity, and TransPlant capability and 3) creatively structuring transactions around FlexFactories, XDRs and its FlexFactory manufacturing services.

Based in Marlborough, Massachusetts, Xcellerex is backed by an experienced management team and top-tier venture investors including Kleiner Perkins Caufield & Byers, VantagePoint Venture Partners and SCG Capital. For more information, please visit the company’s website at http://www.xcellerex.com

About G-Con, LLC

G-Con, LLC is a Texas-based company dedicated to bringing new technologies and processes to the therapeutic manufacturing industry. The Company’s mission is to revolutionize the biomanufacturing industry by providing comprehensive GMP manufacturing solutions that are cheaper to build, flexible, cheaper to maintain and easier to operate than any existing solution on the market. The company’s principals have 30 years experience in pharmaceutical facility design and operation and have brought first in class therapeutics from concept to the market. For additional information, visit the Company’s website at www.gconbio.com.